Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03486067 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03486067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03486067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 1
Overall status
Terminated
Start date
April 3, 2018
Completion date
March 18, 2025
Enrollment
183 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma